BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36325966)

  • 1. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
    Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
    Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
    Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
    Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
    Liu Q; Huang Q; Yu Z; Wu H
    Clin Respir J; 2022 Mar; 16(3):216-225. PubMed ID: 35081265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL; Jia RN; Han K; Zhang YX
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903
    [No Abstract]   [Full Text] [Related]  

  • 6. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S; Yan B; Zheng J; Zhao J; Zhou J
    Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
    Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
    J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 11. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?
    Ma Z; Wang Z; Li Y; Zhang Y; Chen H
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2717-2722. PubMed ID: 35524781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics.
    Zhu J; Fan Y; Xiong Y; Wang W; Chen J; Xia Y; Lei J; Gong L; Sun S; Jiang T
    Exp Mol Med; 2022 Nov; 54(11):2060-2076. PubMed ID: 36434043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
    Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
    Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.
    Kobayashi Y; Mitsudomi T; Sakao Y; Yatabe Y
    Ann Oncol; 2015 Jan; 26(1):156-161. PubMed ID: 25361983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma.
    Lin Y; Li D; Hui H; Miao H; Luo M; Roy B; Chen B; Zhang W; Shao D; Ma D; Jie Y; Qiu F; Li H; Jiang B
    Front Oncol; 2024; 14():1389618. PubMed ID: 38803537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
    Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
    Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.